IPCA Laboratories Limited — Q3 FY25 earnings call

Call held 13 Feb 2025

Management summary

Ipca Labs reported a strong Q3 FY25 with significant margin expansion across both standalone and consolidated entities, driven by improved product mix, operational efficiencies, and Unichem's turnaround. Domestic formulation and API businesses showed robust growth. However, the generics segment faced headwinds in South Africa and the institutional antimalarial business is under pressure due to US aid cuts, while new capacities await regulatory clearances.

Highlights

  • Standalone EBITDA margin at 24.25% in Q3 FY25, up 5.73% from 18.52% in Q3 FY24.

  • Consolidated EBITDA margin at 19.87% in Q3 FY25, up 3.77% from 16.1% in Q3 FY24.

  • Domestic formulation business delivered ~13% growth for the quarter, outperforming the market's 7.4% growth.

  • API business delivered ~12% growth for the quarter.

  • Unichem's EBITDA margin improved to almost ~12% from ~5% last year, driven by operational improvements and buying efficiencies.

  • Material cost ratio (standalone) improved to 27.62% in Q3 FY25 from 28.9% in Q1 and 29.59% in Q2, and 28.73% for 9 months FY25 vs 32% last year.

Concerns

  • Generic business saw a decline of INR 80 crores in South Africa due to lost tender orders, reducing annual business from INR 120 crores to INR 40 crores.

  • Institutional antimalarial business faces uncertainty due to US aid cuts, with INR 40 crores of business potentially impacted.

  • Iran business has ceased, resulting in a loss of INR 75-80 crores in annual revenue.

  • Dewas capacity utilization is currently low at 35-40% due to pending regulatory approvals and inspections.

Key financials

  1. Standalone EBITDA Margin 24.3% +5.7%YoY
  2. Consolidated EBITDA Margin 19.9% +3.8%YoY
  3. Domestic Formulation Growth 13%
  4. Overall Formulation Growth 6%
  5. API Business Growth 12%
  6. Standalone Material Cost Ratio 27.6%

What they filed

Q1 FY27: revenue up 21.3%, net profit up 42.4% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,811 1,663 1,638 1,747 1,930 +7%1,845 +11%1,814 +11%2,119 +21%
EBITDA402 411 359 407 465 +16%477 +16%431 +20%578 +42%
Net profit244 268 -65 262 305 +25%303 +13%262 +503%373 +42%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Domestic Formulation
    13% Growth
  • API Business
    12% Growth
  • Overall Pharma Market
    7.4% Growth
  • Acute Segment (Market)
    6% Growth
  • Acute Segment (Ipca)
    8.7% Growth
  • Chronic Segment (IPM)
    9.7% Growth
  • Chronic Segment (Ipca)
    17.1% Growth
  • ROW Market Business
    50% Growth
  • Pain Portfolio (9 months)
    14% Growth
  • Antibacterial
    1% Growth
  • Cough and Cold
    4% Growth
  • Overall Internal Growth (9 months)
    12% Growth

Capital allocation

high confidence
  • Debt Gross ₹900 Cr · Net ₹300 Cr
    Overall, I think gross debt is around INR900 crores in the balance sheet for Ipca standalone. And we have almost around INR600 crores of cash. So net of cash, we have around INR300 crores kind of debt overall, cash what is available with us. And I think next financial year, practically that number will become nil because debt repayment and all, overall cash holding and if you see, net debt would be practically zero. Consolidated level, there are hardly any borrowings in Unichem. It's not a maybe less than about $12 million, $13 million -- $30 million overall.
  • Liquidity Cash ₹600 Cr Net debt expected to be nil next financial year due to debt repayment and cash holding.
    And we have almost around INR600 crores of cash. So net of cash, we have around INR300 crores kind of debt overall, cash what is available with us. And I think next financial year, practically that number will become nil because debt repayment and all, overall cash holding and if you see, net debt would be practically zero.

Guidance & targets

Margin

  • Standalone EBITDA Margin Margin · FY25 · High confidence 23-24%

    Previously 21% → 23-24%

    And overall guidance for the year was around 21%, but for whole of our financial year our EBITDA is likely to remain in the range of around 23% to 24%.

    — A.K. Jain

  • Consolidated EBITDA Margin Margin · FY25 · High confidence 19.18-19.5%

    Previously 18% → 19.18-19.5%

    As against overall, our guidelines was around 18% for the year. As against we are delivering around 19.18%. And hopefully, 19.18% to 19.5% this is the range in which the overall consolidated margins would remain for the current financial year.

    — A.K. Jain

Growth

  • API Business Growth Growth · FY25 · Medium confidence 8-10%
    And overall, for the 9 months, it is at 28.73%. So more or less, for the fourth quarter also, it will remain around 28.73% that's the kind of broadly around that 28% to 29% is the -- what is the overall. So -- and last year, for the first 9 months, this ratio was around 32%. So if you look at 9 months versus this, so there is almost around improvement of 3.37%. And so that improvement is there in overall in the current financial year.

    — A.K. Jain

  • UK Business Growth Growth · Next Financial Year · Medium confidence 15-17%
    And I think we have a lot of launches also in pipeline. So I think in U.K. numbers, we will see around 15% to 17% kind of overall growth in next financial year.

    — A.K. Jain

  • Promotional Market Business Growth Growth · FY25 · Medium confidence 8-9%
    But overall, on this promotional market business, we are looking for around 8% to 9% growth for the whole of the financial year.

    — A.K. Jain

  • Domestic Formulation Growth (vs IPM) Growth · Next few years · Medium confidence 1.5x IPM growth
    So more or less, whatever our growth, 1.5x IPM growth, hopefully, we should continue with that coming few years.

    — Harish Kamath

  • Pain Management Growth Growth · Next 3-4 years · Medium confidence 13-14%
    Yes, definitely, unless pain management grows 13%, 14%, I can't grow 1.5x the market growth. So that is almost 52% of my overall business.

    — Harish Kamath

Tax Rate

  • Effective Tax Rate Tax Rate · FY25 · Medium confidence 27-28%

    From 25% today

    Overall tax rate for us is 25%, but some kind of disallowances on CSR and also on the marketing cost and all wise, I think overall tax will remain around 27% to 28% kind of thing.

    — A.K. Jain

Capacity Utilization

  • Unichem Facilities Full Utilization Capacity Utilization · Long-term · Medium confidence 4-5 years
    So next 4 to 5 years, I don't think they will need any further capacity other than routine capacity improvement plans and all.

    — Harish Kamath

R&D Spend

  • R&D Spend as % of Revenue R&D Spend · Future · Medium confidence 4%

    From 3-3.25% today

    Currently, both Ipca and Unichem put together, it's around 3%, 3.25% kind of R&D cost. That cost is likely to move to around 4%.

    — A.K. Jain

Product Launches

  • ANDA Filings (Ipca) Product Launches · Every year · Medium confidence 5-6 per year
    So I think every year, we should be able to now file 5, 6 kinds of Ipca ANDAs, so Unichem will also continue to do that kind of number.

    — A.K. Jain

Market context

  • Europe Business Growth Growth · Ongoing · Medium confidence Double-digit
    And sir, Europe will continue to grow at these double-digit growth rates? Yes.

    — A.K. Jain

What to watch in Q4 FY25

Unichem EBITDA margin improvement

next quarter
Current ~12%
Target Continued improvement

Why it matters

Unichem's margin improvement is a key driver for consolidated profitability and validates the acquisition synergy.

And now their EBITDA margin has also improved to almost around close to 12%. So that is also helping in consolidations to deliver the better margins.

Risks & concerns

  • Loss of Iran business

    high

    Previous INR 75-80 crores business in Iran has ceased due to payment issues (lack of dollars/currencies).

    Management acknowledged

  • Impact of US aid cuts on institutional antimalarial business

    medium

    INR 40 crores of business related to US aid programs is under assessment for potential impact.

    Analyst acknowledged

  • Decline in South Africa generic business

    medium

    INR 80 crores decline in annual business due to lost tender orders, reducing revenue from INR 120 crores to INR 40 crores.

    Management acknowledged

  • Low capacity utilization at Dewas due to pending regulatory approvals

    medium

    Dewas capacity is currently at 35-40% utilization as regulatory approvals and inspections are pending.

    Management acknowledged

Q&A highlights

6 direct
Gross margin sustainability and drivers Direct
See, gross margin this particular quarter was exceptionally high mainly because the overall, let's say, turnover in this quarter has grown by around 10%. Material cost, there is a significant reduction, against 10% growth, material cost has come down by around 5%. So that is the impact.

Analyst sought clarity on the exceptional gross margin, and management attributed it to product mix improvement and lower material costs, indicating sustainability.

Asked by Surya Narayan Patra

Unichem's contribution to consolidated gross margin Direct
Talking about standalone side, as far as Unichem is concerned, last year, around same time, they were having around 5% EBITDA margin. And now their EBITDA margin has also improved to almost around close to 12%. So that is also helping in consolidations to deliver the better margins.

Confirms Unichem's significant turnaround and its positive impact on consolidated margins, validating the acquisition strategy.

Asked by Surya Narayan Patra

Progress of US business product launches and Unichem integration Partial
As far as Ipca portfolio in Unichem is concerned, let's say I would say that we have shipped around 4 products till now and almost around 7 to 8 products are in pipeline. So -- and mostly, the stocks has gone in the current quarter and end of last quarter. So nothing meaningful has happened as far as the overall consolidated numbers are concerned.

Analyst inquired about US market traction post-integration; management indicated initial shipments and pipeline but acknowledged minimal financial impact so far, suggesting a longer gestation period.

Asked by Surya Narayan Patra

Impact of US aid cuts on institutional antimalarial business Partial
So that business is around INR40 crores, yes. So how much of that will impact, right now it's difficult to say, but yes, that is the number which we have, which is relating to the U.S. aids business.

Analyst probed a potential risk; management quantified the exposure but could not fully assess the impact, highlighting uncertainty.

Asked by Surya Narayan Patra

Reasons for weakness in generic business Direct
By and large, this lower generic numbers are mainly because of South Africa. We were doing a business of around INR120 crores in South Africa in a year. I think this year, the number maybe around INR40 crores-or-so. So there will be almost around INR80 crores kind of INR75 crores to INR80 crores kind of decline in South Africa business because of some tender orders are lost and all those kind of things are there.

Management provided a specific reason and quantified the impact of lost tenders in South Africa on the generic business.

Asked by Shiva

API pricing pressure and outlook Direct
Right now, we have not noticed any kind of pricing pressure. Somewhere some solvent prices have moved, other solvent prices have come down. I think on the chemical side, there are hardly any kind of movement. And intermediate side, we have seen slight improvement in few, but we have seen reduction in many more. So overall basis, I would say this is a neutral. And I don't foresee that in next 2 quarters also, there could be any kind of further improvements in the overall, let's say, increase in the prices.

Analyst sought clarity on a key input cost; management indicated a neutral outlook on API pricing for the next two quarters, suggesting stability.

Asked by Tushar

Productivity of new MR additions and divisions Direct
Overall, I think we have around 6,700 people currently. And overall productivity per month is around 4,45,000. It was around 4,25,000 with 6,300 people. Currently, 6,700 and 4,45,000 per month.

Analyst inquired about the efficiency of recent hiring; management provided current and past MR productivity metrics, indicating improvement.

Asked by Shiva

Strategy for new growth areas and R&D focus Direct
See, the new areas at number one is, let's say, we are leaders in pain management. And as far as the orthopedics and dentals are concerned, we have significant leadership there on those kind of products. And now we are trying to leverage those relationships and now started a new division called Flexicare for adding the people -- adding the product for which are used by orthopedics for other indications because pain is one area, but they prescribe a lot of other products.

Analyst asked about future growth drivers; management outlined new divisions in orthopedics (Flexicare), cardiology, and cosmetic dermatology, along with a focus on ANDA filings.

Asked by Saion Mukherjee

3 min read 6 chapters

Detailed narrative

Q3 FY25 Financial Performance and Margin Expansion

Ipca Labs reported a strong Q3 FY25 with significant margin improvement. Standalone EBITDA margin increased by 5.73% to 24.25% from 18.52% in Q3 FY24. On a consolidated basis, EBITDA margin expanded by 3.77% to 19.87% from 16.1% in Q3 FY24. For the nine months of FY25, standalone EBITDA margin was 23.14% (up 3.59% YoY) and consolidated EBITDA margin was 19.18% (up 1.84% YoY). This improvement was primarily driven by a favorable product mix and a 5% reduction in material costs against a 10% turnover growth.

Domestic Formulation and API Business Growth

The domestic formulation business delivered a robust 13% growth for the quarter, significantly outpacing the overall pharma market growth of 7.4%. Ipca's growth in the acute segment was 8.7% against a market growth of 6%, and in the chronic segment, it grew by 17.1% compared to IPM's 9.7%. The API business also contributed positively with a 12% growth for the quarter. Overall formulation business grew by 6% for the quarter. The company's pain portfolio grew by 14% for the first nine months of the current year.

Unichem Integration and US Market Strategy

Unichem's EBITDA margin has significantly improved to approximately 12% from around 5% last year, largely due to operational efficiencies and buying synergies post-acquisition. While Ipca has shipped about 4 products to the US market through Unichem and has 7-8 products in the pipeline, the financial impact on overall consolidated numbers has been minimal so far. The company expects to see 15-17% growth in the UK market next financial year and double-digit growth in Europe. Full capacity utilization at Unichem facilities is anticipated within 4-5 years.

Capital Structure and Debt Management

On a standalone basis, Ipca Labs has a gross debt of approximately INR 900 crores and cash of INR 600 crores, resulting in a net debt of INR 300 crores. Management expects the standalone net debt to become nil in the next financial year due to debt repayment and cash accumulation. Unichem has minimal borrowings, estimated at around $12-13 million, with an overall consolidated debt of approximately $30 million.

Strategic Growth Initiatives and R&D Focus

Ipca is focusing on new growth areas by leveraging its leadership in pain management and orthopedics. A new division, 'Flexicare,' has been launched with 150 people added and another 200 planned, targeting breakeven next year. The company plans to add another division in cardiology with 300 people and one in cosmetic dermatology next financial year. R&D spend is projected to increase to 4% of revenue from the current 3-3.25%, supporting a target of 5-6 ANDA filings per year for Ipca.

Key Risks and Outlook

The company faces challenges in its generic business, particularly in South Africa, where lost tender orders led to an INR 80 crores decline. The institutional antimalarial business, with INR 40 crores linked to US aid, faces uncertainty due to recent US aid cuts. Furthermore, the INR 75-80 crores business in Iran has ceased due to payment issues. Capacity utilization at the Dewas plant remains low at 35-40% due to pending regulatory approvals. Despite these, management has revised its FY25 standalone EBITDA margin guidance to 23-24% (from 21%) and consolidated EBITDA margin to 19.18-19.5% (from 18%).

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls